Standout Papers

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-82... 2019 2026 2021 2023 256
  1. The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy (2019)
    Takashi Nakada, Kiyoshi Sugihara et al. Chemical and Pharmaceutical Bulletin

Immediate Impact

1 from Science/Nature 70 standout
Sub-graph 1 of 23

Citing Papers

An Update on the Nitrogen Heterocycle Compositions and Properties of U.S. FDA-Approved Pharmaceuticals (2013–2023)
2024 Standout
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
2024 Standout
1 intermediate paper

Works of Yuki Abe being referenced

The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
2019 Standout

Author Peers

Author Last Decade Papers Cites
Yuki Abe 162 167 91 241 29 551
Luca Riva 114 76 71 85 33 470
Hung‐Ming Wang 106 51 71 164 20 503
Zhijia Wang 74 44 171 174 28 595
Kentaro Okuda 193 51 93 237 29 502
Yuanyuan Liu 68 38 149 268 29 558
Frank Aboubakar Nana 157 29 102 172 29 470
Kyong Yeun Jung 51 138 119 119 36 635
Matthew Bower 172 47 63 248 19 600
Mariko Negi 145 134 79 163 30 553
Theodora Kerenidi 133 61 202 165 28 633

All Works

Loading papers...

Rankless by CCL
2026